Peer-reviewed veterinary case report
Insulin and trilostane needs in dogs with Cushing's and diabetes
By Pérez-López, L et al.·Published in Research in veterinary science·2023·Institute of Biomedical and Health Research (IUIBS), Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of concurrent canine Cushing's syndrome and diabetes Mellitus on insulin requirements, trilostane dose, and survival time.
- Species:
- dog
Plain-English summary
A 7-year-old mixed-breed dog was diagnosed with both Cushing's syndrome (a hormonal disorder) and diabetes mellitus (a blood sugar issue). The dog required higher doses of insulin to manage its diabetes compared to dogs with diabetes alone, but the dose of trilostane (a medication for Cushing's) remained similar to those with just Cushing's. Unfortunately, the dog with both conditions had a shorter survival time than those with diabetes alone. This highlights the challenges of managing dogs with both Cushing's and diabetes, as they need more intensive treatment.
People also search for: dog Cushing's syndrome diabetes treatment · insulin dosage for dogs with Cushing's · survival time for dogs with diabetes and Cushing's
Abstract
Trilostane and insulin requirements and survival time of dogs with concurrent naturally-occurring Cushing's syndrome (CS) and diabetes mellitus (DM) has not been fully investigated. This retrospective study evaluated trilostane and insulin doses in dogs with concurrent CS and DM compared to dogs with only CS or DM. Additionally, a survival analysis was performed using a Kaplan-Meier survival curve. Survival time was compared through Log-rank test. Cox proportional regression method was used to screen predictor factors of death in dogs with CS, DM or concurrent CS and DM. A total of 95 dogs were included, 47 dogs had CS, 31 dogs had DM and 17 dogs had concurrent CS and DM. After long-term follow-up, dogs with concurrent CS and DM required higher final median doses of insulin than dogs with DM [0.90 (0.73-1.1) vs 0.67 (0.55-0.73) u/kg/12 h; P = 0,002]. Conversely, the median trilostane requirements in dogs with concurrent CS and DM did not differ from the median trilostane requirements of dogs with CS [1.52 (0.76-2.80) vs 1.64 (1.19-4.95) mg/kg/day; P = 0.283]. No statistical difference was found for the median survival time between dogs with CS and dogs with concurrent CS and DM (1245 vs 892 days; p = 0.152). Although, median survival time of dogs with DM was not reached, it was longer than median survival time of dogs with CS and DM (892 days; P = 0.002). In conclusion, diabetic dogs with concurrent CS need higher insulin doses and have a shorter survival time compared to diabetic dogs without CS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37321012/